Celgene management restructuring
Executive Summary
Celgene Chairman and CEO John Jackson will step down as CEO effective May 1, 2006, but will continue serving as chairman of the board of directors. President and COO Sol Barer will assume the position of CEO, while senior VP and CFO Robert Hugin will take over Barer's current role. The biopharmaceutical company said it is actively seeking a new CFO and hopes to fill the position by May. The new management team will be responsible for overseeing the launch of Revlimid; the transition announcement coincided with FDA approval of Revlimid (lenalidomide) Dec. 27 for the treatment of blood cancer...
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.